Hanmi Science Valuation

Q: What is the Fair Price of A008930 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A008930 (₩32550) is trading above our estimate of [[fair value]] (₩16143.1)

Is A008930 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A008930 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A008930 (₩32550) is trading above our estimate of fair value (₩16143.1)

Significantly Below Fair Value: A008930 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A008930?

Key metric: As A008930 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A008930. This is calculated by dividing A008930's market cap by their current earnings.
What is A008930's PE Ratio?
PE Ratio	21x
Earnings	₩104.96b
Market Cap	₩2.20t

A008930 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	44.6x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A008930's PE Ratio compare to its peers?

The above table shows the PE ratio for A008930 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	42.5x
A299170 WSI	40.2x	n/a	₩42.9b
A214150 CLASSYS	35.4x	24.1%	₩3.2t
A078160 MEDIPOST	61.2x	n/a	₩280.6b
A085370 Lutronic	33.1x	26.4%	₩949.5b
A008930 Hanmi Science	21x	n/a	₩2.2t

Price-To-Earnings vs Peers: A008930 is good value based on its Price-To-Earnings Ratio (21x) compared to the peer average (42.5x).

Price to Earnings Ratio vs Industry

How does A008930's PE Ratio compare vs other companies in the Asian Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A008930 is expensive based on its Price-To-Earnings Ratio (21x) compared to the Asian Healthcare industry average (20.8x).

Price to Earnings Ratio vs Fair Ratio

What is A008930's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A008930 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	21x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A008930's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Access Bio

₩188.3b

Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

A950130

₩5,570.00

2.0%

-37.1%

Vieworks

₩192.8b

Develops, manufactures, and sells imaging systems and solutions.

A100120

₩21,000.00

3.4%

-24.2%

Wonbiogen

₩43.5b

Develops and sells medical equipment in South Korea.

A307280

₩1,225.00

-1.1%

-21.6%